WELCOME
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi counts among the leading suppliers in the U.S. market.
All over the world more than 24,000 employees are committed to improving the quality of life of critically and chronically ill patients with innovative products for patients in hospitals and outpatients.
News
April 23, 2013
American Nurses Foundation Announces New Scholarship Fund Supported by Grant from Fresenius Kabi
January 8, 2013
Fresenius Kabi USA Launches Treatment for Acetaminophen Overdose
October 1, 2012
Fresenius Kabi Announces Availability of Acetylcysteine Solution, USP, 20%
August 9, 2012
Fresenius Kabi Announces Launch of Oxaliplatin Injection, USP Latest APP Oncology Product Now Available



